Braveheart Bio Insider Trades
NASDAQ: BRVEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Last 12 months
- Purchases
- 13 · $159.03M
- Sales
- 0 · $0
- Shares bought / sold
- 8.84M / 0
- Net activity
- Net buying $159.0 million
Braveheart Bio insider activity
Over the last 12 months, Braveheart Bio insiders reported 19 transactions on SEC Form 4: 13 open-market purchases and 0 sales. Insiders bought $159.0 million and sold $0 worth of stock, for net insider buying of $159.0 million. The most recent filing shows ORBIMED ADVISORS LLC & OrbiMed Capital GP IX LLC & OrbiMed Genesis GP LLC (Director) reporting a transaction in 9,132,420 shares on Aug 7, 2026.
Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put BRVE's ownership changes in context.
Summary generated from market data by MetaCap's automated system. Methodology
BRVE insider transactions
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Aug 7, 2026 | Lubner David CharlesDirector | Buy | 55,555 | $999.99K | Form 4 |
| Aug 7, 2026 | Murdoch TravisCEO and President | Buy | 83,333 | $1.50M | Form 4 |
| Aug 7, 2026 | Anderson Michele A.Chief Development Officer | Buy | 1,111 | $20.00K | Form 4 |
| Aug 7, 2026 | Malek David IDirector | Buy | 4,166 | $74.99K | Form 4 |
| Aug 7, 2026 | Viehbacher ChristopherDirector | Buy | 83,333 | $1.50M | Form 4 |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. & Forbion Growth III Management B.V. & Forbion Ventures Fund VII Cooperatief U.A. & Forbion Ventures VII Management B.V.10% Owner | Buy | 1,680,000 | $30.24M | Form 4 |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. & Forbion Growth III Management B.V. & Forbion Ventures Fund VII Cooperatief U.A. & Forbion Ventures VII Management B.V.10% Owner | Buy | 1,920,000 | $34.56M | Form 4 |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. & Forbion Growth III Management B.V. & Forbion Ventures Fund VII Cooperatief U.A. & Forbion Ventures VII Management B.V.10% Owner | Conversion | 7,990,867 | — | Form 4 |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. & Forbion Growth III Management B.V. & Forbion Ventures Fund VII Cooperatief U.A. & Forbion Ventures VII Management B.V.10% Owner | Conversion | 9,132,420 | — | Form 4 |
| Aug 7, 2026 | Rickey James PaulChief Financial Officer | Buy | 27,777 | $499.99K | Form 4 |
| Aug 7, 2026 | Jiangsu Hengrui Pharmaceuticals Co., Ltd.10% Owner | Conversion | 7,420,091 | — | Form 4 |
| Aug 7, 2026 | Chimovits ErezDirector | Buy | 273,333 | $4.92M | Form 4 |
| Aug 7, 2026 | Chimovits ErezDirector | Buy | 1,666,667 | $30.00M | Form 4 |
| Aug 7, 2026 | Chimovits ErezDirector | Conversion | 9,132,420 | — | Form 4 |
| Aug 7, 2026 | AH Bio Fund IV, L.P. & AH Equity Partners Bio IV, L.L.C. & Andreessen Marc L & HOROWITZ BENJAMIN A10% Owner | Buy | 1,100,000 | $19.80M | Form 4 |
| Aug 7, 2026 | AH Bio Fund IV, L.P. & AH Equity Partners Bio IV, L.L.C. & Andreessen Marc L & HOROWITZ BENJAMIN A10% Owner | Conversion | 9,132,420 | — | Form 4 |
| Aug 7, 2026 | ORBIMED ADVISORS LLC & OrbiMed Capital GP IX LLC & OrbiMed Genesis GP LLCDirector | Buy | 273,333 | $4.92M | Form 4 |
| Aug 7, 2026 | ORBIMED ADVISORS LLC & OrbiMed Capital GP IX LLC & OrbiMed Genesis GP LLCDirector | Buy | 1,666,667 | $30.00M | Form 4 |
| Aug 7, 2026 | ORBIMED ADVISORS LLC & OrbiMed Capital GP IX LLC & OrbiMed Genesis GP LLCDirector | Conversion | 9,132,420 | — | Form 4 |
Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4